Myelodysplastic syndrome, which refers to a group of blood disorders, affects an estimated 60,000 people in the U.S. The abnormal or malignant precursor cells in the bone marrow proliferates resulting in a disordered and ineffective production of the myeloid lineage, which includes red blood cells, white blood cells and platelets in patients with myelodysplastic syndrome (MDS). Reblozyl, Inqovi, Vidaza, Dacogen, and Revlimid are some of the FDA-approved treatments for MDS.
The stock we are bringing to your attention is that of a late-stage clinical biopharmaceutical company developing a drug for lower risk myelodysplastic syndromes - Geron Corp. (GERN).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com